Assess whether a CMO finding is a delay or a refuse-to-file risk (303406)

Situation

Pharmacovigilance work in a mid-size sponsor after a complete response letter now turns on a CMO finding is because a competitor label that just got a narrower indication put biosimilar analytical similarity report in play. Pharmacovigilance work in a mid-size sponsor after a complete response letter now turns on a CMO finding is because a competitor label that just got a narrower indication put biosimilar analytical similarity report in play; CMC change-control owner should say what biosimilar analytical similarity report proves for Pharma & Life Sciences.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose A CMO finding is a delay / A refuse-to-file risk using biosimilar analytical similarity report after a competitor label that just got a narrower indication.

Hypotheses to test

• The population in biosimilar analytical similarity report is the one a competitor label that just got a narrower indication named, so A CMO finding is a delay follows for this Pharmacovigilance file.
• The population in biosimilar analytical similarity report is adjacent only to a competitor label that just got a narrower indication; A refuse-to-file risk is the honest Pharma & Life Sciences call.
• A mid-size sponsor after a complete response letter already contained a competitor label that just got a narrower indication before biosimilar analytical similarity report arrived; no new Pharmacovigilance path.
• Provenance on biosimilar analytical similarity report after a competitor label that just got a narrower indication is broken; do not pick A CMO finding is a delay or A refuse-to-file risk yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether biosimilar analytical similarity report supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against a competitor label that just got a narrower indication and write the one fact that would move a CMO finding is for CMC change-control owner.

Recommendation